Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study

Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yinuo, Li, Xuemei, Zhao, Xinya, Liu, Yiqing, Zhao, Tong, Zhu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234691/
https://www.ncbi.nlm.nih.gov/pubmed/37269896
http://dx.doi.org/10.1016/j.clinre.2023.102150
_version_ 1785052555647123456
author Yang, Yinuo
Li, Xuemei
Zhao, Xinya
Liu, Yiqing
Zhao, Tong
Zhu, Qiang
author_facet Yang, Yinuo
Li, Xuemei
Zhao, Xinya
Liu, Yiqing
Zhao, Tong
Zhu, Qiang
author_sort Yang, Yinuo
collection PubMed
description Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity rates and antibody concentrations of anti-SARS-CoV-2 NAbs were similar among patients with different severity of CLD 6 months after the third vaccination. In addition, older CLD patients appeared to have lower antibody responses. These data might be helpful to inform vaccine decisions for patients with chronic liver disease.
format Online
Article
Text
id pubmed-10234691
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-102346912023-06-02 Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study Yang, Yinuo Li, Xuemei Zhao, Xinya Liu, Yiqing Zhao, Tong Zhu, Qiang Clin Res Hepatol Gastroenterol Letter to the Editor Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity rates and antibody concentrations of anti-SARS-CoV-2 NAbs were similar among patients with different severity of CLD 6 months after the third vaccination. In addition, older CLD patients appeared to have lower antibody responses. These data might be helpful to inform vaccine decisions for patients with chronic liver disease. Elsevier Masson SAS. 2023-08 2023-06-02 /pmc/articles/PMC10234691/ /pubmed/37269896 http://dx.doi.org/10.1016/j.clinre.2023.102150 Text en © 2023 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Yang, Yinuo
Li, Xuemei
Zhao, Xinya
Liu, Yiqing
Zhao, Tong
Zhu, Qiang
Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study
title Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study
title_full Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study
title_fullStr Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study
title_full_unstemmed Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study
title_short Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study
title_sort long-term antibody response to inactivated sars-cov-2 vaccination in patients with chronic liver disease: a multicenter study
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234691/
https://www.ncbi.nlm.nih.gov/pubmed/37269896
http://dx.doi.org/10.1016/j.clinre.2023.102150
work_keys_str_mv AT yangyinuo longtermantibodyresponsetoinactivatedsarscov2vaccinationinpatientswithchronicliverdiseaseamulticenterstudy
AT lixuemei longtermantibodyresponsetoinactivatedsarscov2vaccinationinpatientswithchronicliverdiseaseamulticenterstudy
AT zhaoxinya longtermantibodyresponsetoinactivatedsarscov2vaccinationinpatientswithchronicliverdiseaseamulticenterstudy
AT liuyiqing longtermantibodyresponsetoinactivatedsarscov2vaccinationinpatientswithchronicliverdiseaseamulticenterstudy
AT zhaotong longtermantibodyresponsetoinactivatedsarscov2vaccinationinpatientswithchronicliverdiseaseamulticenterstudy
AT zhuqiang longtermantibodyresponsetoinactivatedsarscov2vaccinationinpatientswithchronicliverdiseaseamulticenterstudy

Ejemplares similares